Related Experiment Video
Updated: Jun 23, 2026

Experimental Assessment of Mouse Sociability Using an Automated Image Processing Approach
Published on: May 15, 2016
3,4-Methylenedioxymethamphetamine Increases Affiliative Behaviors in Squirrel Monkeys in a Serotonin 2A
Elizabeth G Pitts1, Adelaide R Minerva1, Erika B Chandler1
1Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Abstract:
3,4-Methylenedioxymethamphetamine (MDMA) increases sociality in humans and animals. Release of serotonin (5-HT) is thought to have an important role in the increase in social behaviors, but the mechanisms underlying these effects are poorly understood. Despite the advantages of nonhuman primate models, no studies have examined the mechanisms of the social effects of MDMA in nonhuman primates. The behavior and vocalizations of four group-housed squirrel monkeys were examined following administration of MDMA, its enantiomers, and methamphetamine. 5-HT receptor antagonists and agonists were given as drug pretreatments. Data were analyzed using linear mixed-effects models. MDMA and its enantiomers increased affiliative social behaviors and vocalizations, whereas methamphetamine had only modest effects on affiliative behaviors. Pretreatment with a 5-HT2A receptor antagonist and a 5-HT2C receptor agonist attenuated the MDMA-induced increase in social behaviors, while a 5-HT1A receptor antagonist did not alter affiliative vocalizations and increased MDMA-induced social contact. Nonhuman primates show MDMA-specific increases in affiliative social behaviors following MDMA administration, in concordance with human and rodent studies. MDMA-induced increases in social behaviors are 5-HT2A, but not 5-HT1A, receptor dependent. Understanding the neurochemical mechanisms mediating the prosocial effects of MDMA could help in the development of novel therapeutics with the unique social effects of MDMA but fewer of its limitations.
Insights
3,4-Methylenedioxymethamphetamine (MDMA) enhances social behavior in squirrel monkeys, mediated by serotonin 5-HT2A receptors. This research clarifies MDMA
Area of Science:
- Neuroscience
- Primate Behavior
- Pharmacology
Background:
- 3,4-Methylenedioxymethamphetamine (MDMA) is known to increase sociality in humans and rodents.
- The precise neurochemical mechanisms, particularly involving serotonin (5-HT), underlying MDMA's prosocial effects remain poorly understood.
- Nonhuman primate models offer unique advantages for studying these mechanisms, yet have not been utilized for MDMA's social effects.
Purpose of the Study:
- To investigate the neurochemical mechanisms of MDMA's social effects in nonhuman primates.
- To examine the specific roles of serotonin receptor subtypes in mediating MDMA-induced social behaviors.
- To compare the social effects of MDMA with methamphetamine in squirrel monkeys.
Main Methods:
- Behavioral and vocalization analyses were conducted on four group-housed squirrel monkeys.
- Subjects received MDMA, its enantiomers, or methamphetamine, with and without pretreatments of 5-HT receptor antagonists and agonists.
- Data were analyzed using linear mixed-effects models to determine statistical significance.
Main Results:
- MDMA and its enantiomers significantly increased affiliative social behaviors and vocalizations in squirrel monkeys.
- Methamphetamine exhibited only modest effects on affiliative behaviors.
- Pretreatment with a 5-HT2A receptor antagonist and a 5-HT2C receptor agonist attenuated MDMA's prosocial effects, while a 5-HT1A antagonist did not alter vocalizations but increased social contact.
Conclusions:
- Nonhuman primates demonstrate MDMA-specific increases in affiliative social behaviors, consistent with human and rodent findings.
- MDMA-induced prosocial effects in this model are dependent on 5-HT2A receptor activity, but not 5-HT1A receptors.
- Understanding these neurochemical pathways could inform the development of novel therapeutics targeting social behavior with fewer limitations.
Related Concept Videos
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Drugs Affecting Neurotransmitter Release or Uptake

